Importantly, co-existent hypertension is an identified risk factor for other cardiotoxicities such as Human Epidermal Growth Factor receptor 2 (HER2-associated) LVSD cardiotoxicity [28] though it is not known whether treating BP to conventional or more aggressive targets immediately prior to receiving cancer therapeutics reduces the risk of these cardiotoxicities as has been shown in other populations of diabetic, non-diabetic and chronic kidney disease patients [15,16,17]. The gene discussed is ERBB2; the disease is cancer.